Zacks: Analysts Anticipate Kalvista Pharmaceuticals Inc (KALV) to Announce -$0.45 EPS

Wall Street brokerages forecast that Kalvista Pharmaceuticals Inc (NASDAQ:KALV) will report earnings per share of ($0.45) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Kalvista Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.79) and the highest is ($0.26). Kalvista Pharmaceuticals reported earnings of ($0.06) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 650%. The business is expected to issue its next quarterly earnings report on Tuesday, July 30th.

According to Zacks, analysts expect that Kalvista Pharmaceuticals will report full year earnings of ($1.43) per share for the current fiscal year, with EPS estimates ranging from ($2.11) to ($1.16). For the next financial year, analysts anticipate that the firm will report earnings of ($2.12) per share, with EPS estimates ranging from ($4.21) to ($1.21). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.22. The firm had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.97 million. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%.

A number of brokerages have recently weighed in on KALV. Zacks Investment Research lowered Kalvista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. BidaskClub upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, May 14th. Roth Capital lifted their price target on Kalvista Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Needham & Company LLC assumed coverage on Kalvista Pharmaceuticals in a research report on Wednesday, March 20th. They issued a “buy” rating and a $35.00 price target for the company. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $30.60.

In other Kalvista Pharmaceuticals news, CFO Benjamin L. Palleiko sold 3,073 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $25.70, for a total transaction of $78,976.10. Following the completion of the transaction, the chief financial officer now owns 33,573 shares in the company, valued at $862,826.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Svlsf Iv, Llc sold 43,378 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $22.91, for a total value of $993,789.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 901,521 shares of company stock valued at $25,597,568. 38.40% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. Flinton Capital Management LLC purchased a new position in shares of Kalvista Pharmaceuticals during the fourth quarter valued at approximately $26,000. Ramsey Quantitative Systems purchased a new position in shares of Kalvista Pharmaceuticals during the fourth quarter valued at approximately $35,000. Bank of Montreal Can purchased a new position in shares of Kalvista Pharmaceuticals during the fourth quarter valued at approximately $90,000. Marshall Wace North America L.P. purchased a new position in shares of Kalvista Pharmaceuticals during the first quarter valued at approximately $175,000. Finally, Morgan Stanley boosted its position in shares of Kalvista Pharmaceuticals by 780.7% during the first quarter. Morgan Stanley now owns 7,486 shares of the specialty pharmaceutical company’s stock valued at $214,000 after buying an additional 6,636 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Shares of Kalvista Pharmaceuticals stock traded up $0.25 during trading on Friday, reaching $23.89. 254,729 shares of the stock traded hands, compared to its average volume of 125,271. The firm has a market cap of $404.11 million, a price-to-earnings ratio of -15.50 and a beta of 2.32. Kalvista Pharmaceuticals has a 52-week low of $7.73 and a 52-week high of $34.92.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Further Reading: Penny Stocks, Risk and Reward Factors

Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.